OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872M deal.
Stocks · News reference
8-K filing — LABCORP HOLDINGS INC. (LH)
Filed: 2026-09-30 AccNo: 0000920148-26-000207 Size: 156 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have entered into an
Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have entered into an
Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 Billion
The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.